XML 45 R36.htm IDEA: XBRL DOCUMENT v3.25.3
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     $ 1,076,000 $ 123,000   $ 5,163,000 $ 26,486,000  
Deferred Revenue     5,104,000     5,104,000   $ 27,290,000
Drug Product Revenue, Net [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     957,000 (262,000)   4,767,000 24,954,000  
Japan [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price, variable consideration from estimated future co-development billing           0    
Europe [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price, variable consideration from estimated future co-development billing           $ 0    
Astellas Agreement [Member] | Japan [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront, non-contingent and time-based payments received   $ 172,600,000            
Additional consideration based on net sales description           the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     105,100,000     $ 105,100,000    
Transaction price, variable consideration from estimated future co-development billing     0 0   0 0  
Changes in revenue from changes to estimated variable consideration           0    
Astellas Agreement [Member] | Japan [Member] | License [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Cash Consideration Received Under Collaboration Agreement     100,300,000     100,300,000    
Astellas Agreement [Member] | Japan [Member] | Co-development, information sharing & committee services [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Cash Consideration Received Under Collaboration Agreement     17,100,000     17,100,000    
Astellas Agreement [Member] | Europe [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront, non-contingent and time-based payments received $ 745,000,000              
Additional consideration based on net sales description         low 20% range      
Aggregate consideration received excluding drug product revenue     685,000,000     685,000,000    
Percentage of joint development costs committed to fund 50.00%              
Changes in revenue from changes to estimated variable consideration     0          
Astellas Agreement [Member] | Europe [Member] | License [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     0 $ 0   0 $ 0  
Cash Consideration Received Under Collaboration Agreement     619,000,000     619,000,000    
Astellas Agreement [Member] | Europe [Member] | Co-development, information sharing & committee services [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Cash Consideration Received Under Collaboration Agreement     $ 288,500,000     $ 288,500,000